ADVENZYMESAdvanced Enzyme Technologies Ltd.

₹310.8+1.40%

Market Cap

₹3,426.64 Cr

Stock P/E

25.03

ROCE

13.76%

ROE

9.79%

Book Value

₹130.12

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
Record quarterly revenue with healthy margins.
•
Human Healthcare growth drives overall top-line, with 21% YoY revenue growth in Q1 FY26.

NEGATIVES

•
Tariff risk on U.S. exports with potential up to INR12.5 crore impact.
•
Margin downside from product mix and tariffs; gross margin likely to be 73–75% going forward.

Peers Summary

Sector Leader

Advanced Enzyme Technologies Ltd. demonstrates solid growth metrics and profitability compared to its peers, but has a relatively high PE ratio. While it shows good revenue growth, its valuation metrics suggest it may not be the most attractive investment compared to others in the sector. Companies like Dr. Reddy's Laboratories and Cipla present stronger overall financial profiles, suggesting they could be better investment choices.

Key Points

• Advanced Enzyme Technologies Ltd. shows strong revenue growth (YoY) of 15.39% but has a high PE ratio of 37.00.
• Dr. Reddy's Laboratories Ltd. and Cipla Ltd. display better profitability and valuation metrics, making them strong contenders in the sector.
• Companies like Divi's Laboratories and Sun Pharmaceutical appear overvalued based on their profitability metrics.

Top Performers

Dr. Reddy's Laboratories Ltd.

Highest ROE (21.76%) and solid growth metrics, making it a top performer.

Cipla Ltd.

Strong profitability metrics with a low PE ratio of 23.73, indicating good value.

Explore

Watchlists

Command Palette